Protagonist Therapeutics, Inc. (PTGX) Cash Flow Statement
Protagonist Therapeutics, Inc. (PTGX) generated $131.2M of operating cash flow over the twelve months to 2026-06-30, spent $615000 on capital expenditure and had free cash flow of $130.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PTGXProtagonist Therapeutics, Inc.Follow PTGX — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 135.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -49.9 | -41.5 | -72.5 | -107.9 | -108.1 | -70.2 | 184.2 | 57.7 | 131.2 | |
| Capital expenditure | 0.5 | 1.0 | 0.5 | 1.1 | 0.8 | 0.6 | 1.4 | 1.6 | -0.6 | |
| Free cash flow | -50.4 | -42.5 | -73.0 | -109.0 | -108.9 | -70.8 | 182.8 | 56.1 | 130.6 | |
| Stock-based compensation | 6.9 | 8.4 | 7.9 | 16.4 | 24.2 | 29.3 | 37.6 | 46.0 | — |
USD millions · SEC XBRL
Protagonist Therapeutics, Inc. — questions
- What is Protagonist Therapeutics, Inc.'s operating cash flow?
- $131.2M over the twelve months to 2026-06-30.
- How much does Protagonist Therapeutics, Inc. spend on capital expenditure?
- $615000 over the twelve months to 2026-06-30.
- What is Protagonist Therapeutics, Inc.'s free cash flow?
- $130.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Protagonist Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.